Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on creating treatments for obesity and associated medical conditions. The company's development efforts span both clinical and preclinical stages, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Its primary development programs feature KAI-9531, an injectable therapy that acts as a GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule designed to be a GLP-1 receptor agonist; and KAI-4729, an injectable therapy functioning as a GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics possesses exclusive global rights for the development and commercialization of four metabolic disease assets, excluding the Greater China region. These therapies are administered via both oral and injectable methods. The company was established in 2024 and is headquartered in Waltham, Massachusetts.